These results provide further evidence that Ch4 degeneration occurs early, preceding hippocampal atrophy, a characteristic marker of neurodegeneration in AD, and highlight the link between Ch4 vulnerability and MTL tau pathology in the preclinical phase of the disease. This evidence concerns the gene MAPT and Atrophy.